Search company, investor...

Calyx Therapeutics

Founded Year

1997

Stage

Series D | Alive

Total Raised

$44.14M

Last Raised

$30M | 21 yrs ago

About Calyx Therapeutics

Calyx Therapeutics is a pharmaceutical company focusing on oral therapies for diabetes and inflammatory diseases. Calyx utilizes natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. The company isolates the biologically active molecule, determines its chemical structure, and aims to develop small molecule analogs. This process aims to reduce the time and investment required to take lead molecules into preclinical and clinical testing.

Headquarters Location

3513 Breakwater Avenue

Hayward, California, 94545,

United States

510-780-1020

Missing: Calyx Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Calyx Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Calyx Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Calyx Therapeutics is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,903 items

B

Biopharma Tech

838 items

Calyx Therapeutics Frequently Asked Questions (FAQ)

  • When was Calyx Therapeutics founded?

    Calyx Therapeutics was founded in 1997.

  • Where is Calyx Therapeutics's headquarters?

    Calyx Therapeutics's headquarters is located at 3513 Breakwater Avenue, Hayward.

  • What is Calyx Therapeutics's latest funding round?

    Calyx Therapeutics's latest funding round is Series D.

  • How much did Calyx Therapeutics raise?

    Calyx Therapeutics raised a total of $44.14M.

  • Who are the investors of Calyx Therapeutics?

    Investors of Calyx Therapeutics include U.S. Venture Partners, Walden International, Morgenthaler Ventures, Scale Venture Partners, Pappas Ventures and 3 more.

  • Who are Calyx Therapeutics's competitors?

    Competitors of Calyx Therapeutics include CytImmune Sciences, Intarcia Therapeutics, Deciphera Pharmaceuticals, Alfama, Catabasis Pharmaceuticals, GC-Rise Pharmaceutical, iPierian, Akebia Therapeutics, GlycoMimetics, DiaKine Therapeutics and 21 more.

Compare Calyx Therapeutics to Competitors

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

M
MAKScientific

is engaged in endocannabinoid research with the ability to address major unmet medical needs for selected diseases with clear competitive advantage over present therapies. The company's mission is the discovery, development and commercialization of therapeutics in the areas of neuropathic, inflammatory and somatic pain, obesity, neuroprotection, and addiction and glaucoma.

M
Morria Biopharmaceuticals

Morria's lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) scheduled for clinical trials in late 2007 and a growing library of additional compounds. Double blind placebo controlled human pilot-studies for contact dermatitis have been successfully completed in Israel .nMorria is also currently engaged in research agreements with three global pharmaceutical leaders in the fields of ophthalmology, eye-care and cardiovascular medicine.

M
Metastatix

Metastatix is a pharmaceutical company based in Atlanta, GA. Founded in 2005, the company is developing and commercializing small- molecule drugs to treat severely debilitating or life-threatening diseases including cancer, HIV infection, and macular degeneration. Per the company, Metastatix has pioneered the development of a series of oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company has licensed its technology from Emory University.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.